title: [Effect of mexidol on the magnitude of a systemic inflammatory response in patients at aortocoronary bypass surgery].
abstract: OBJECTIVE
  to evaluate the efficiency of pharmacological correction of a systemic inflammatory response in patients after coronary bypass surgery, by using mexidol.
  
  
  METHODS
  40 patients with coronary heart disease, who had undergone myocardial revascularization were examined. A study group (n = 20) received mexidol within 5 days before, during, and 5 days after surgery. A control group (n = 20) were given 0.9% NaCl solution. The degree of a systemic inflammatory response was estimated from the levels of C-reactive protein (CRP), the cytokines IL-6, IL-8, and TNF-alpha. The activities of serum enzymes and myoglobin were determined.
  
  
  RESULTS
  after surgery, both groups showed the elevated concentrations of IL-6, IL-8, TNF-alpha, and CRP, but their elevation was statistically significant less in the study group than in the control one (p < 0.05). In both groups, there were increases in the levels of alanine aminotransferase, aspartate aminotransferase, gamma-glutamyl transpeptidase, lactate dehydrogenase, creatinine phosphokinase, and myoglobin, which was statistically significant more apparent in the control group (p < 0.05).
  
  
  CONCLUSIONS
  mexidol diminishes the magnitude of a systemic response after aortocoronary bypass surgery under extracorporeal circulation and has an organ-protective effect.
authors.forename: A A
authors.initials: AA
authors.lastname: Eremenko
authors.forename: T P
authors.initials: TP
authors.lastname: Ziuliaeva
authors.forename: V M
authors.initials: VM
authors.lastname: Egorov
authors.forename: Ia V
authors.initials: IaV
authors.lastname: Sidorenko
authors.forename: M V
authors.initials: MV
authors.lastname: Fominykh
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000975:Antioxidants / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D001026:Coronary Artery Bypass; D003327:Coronary Disease / Q000601:surgery; D016207:Cytokines / Q000276:immunology; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010847:Picolines / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D011183:Postoperative Complications / Q000209:etiology / Q000276:immunology / Q000378:metabolism / Q000517:prevention & control*; D017382:Reactive Oxygen Species / Q000378:metabolism; D018746:Systemic Inflammatory Response Syndrome / Q000209:etiology / Q000276:immunology / Q000378:metabolism / Q000517:prevention & control*; D013997:Time Factors
chemical_list: D000975:Antioxidants; D016207:Cytokines; D010847:Picolines; D017382:Reactive Oxygen Species; C070020:emoxypine succinate